Proteomics

Dataset Information

0

TMT analysis of phosphorylated proteomics of human osteosarcoma cell 143B treated with BEA


ABSTRACT: Phosphorylated proteomics was used to detect the changes of phosphotalin after administration.

INSTRUMENT(S): 6220 Time-of-Flight LC/MS

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

DISEASE(S): Acute Leukemia

SUBMITTER: Ye Geni  

LAB HEAD: Geni Ye

PROVIDER: PXD044225 | Pride | 2023-10-24

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
P202111105148_BEA_1_Slot2-75_1_3945.d.zip Other
P202111105148_BEA_2_Slot2-76_1_3946.d.zip Other
P202111105148_CTL_1_Slot2-73_1_3943.d.zip Other
P202111105148_CTL_2_Slot2-74_1_3944.d.zip Other
txt.rar Other
Items per page:
1 - 5 of 5
altmetric image

Publications

Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway.

Ye Geni G   Jiao Yubo Y   Deng Lijuan L   Cheng Minjing M   Wang Sheng S   Zhang Junqiu J   Ouyang Jie J   Li Yong Y   He Yuxin Y   Tu Zhengchao Z   Wang Zhen Z   Song Xiaojuan X   Wang Chenran C   Qi Qi Q   Zhang Dongmei D   Wang Lei L   Huang Maohua M   Ye Wencai W   Chen Minfeng M  

International journal of biological sciences 20230821 14


Osteosarcoma (OS) patients, particularly those with distant metastasis, experience rapid progression and derive poor survival benefits from traditional therapies. Currently, effective drugs for treating patients with metastatic OS remain scarce. Here, we found that the cyclic hexadepsipeptide beauvericin (BEA) functioned as a new selective TGFBR2 inhibitor with potent antiproliferative and antimetastatic activities against OS cells<i>.</i> Functionally, BEA inhibited TGF-β signaling-mediated pro  ...[more]

Similar Datasets

2023-11-06 | PXD040159 | Pride
2021-12-16 | PXD029941 | Pride
2023-05-10 | PXD039894 | Pride
2024-05-22 | PXD040041 | Pride
2024-06-06 | PXD040262 | Pride
2021-03-30 | PXD020770 | Pride
2022-03-01 | PXD025301 | Pride
2024-10-25 | PXD030254 | Pride
2023-10-03 | PXD044180 | Pride
2022-08-12 | PXD026563 | Pride